JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
نویسندگان
چکیده
| 144 | haematologica | 2009; 94(1) Planker, Rudolf Pihusch, Rudolf Weide, Wolfgang Kern, and Torsten Haferlach MLL Munich Leukemia Laboratory, Munich; Clinic for Stem Cell Transplantation, University Hospital of Hamburg, Hamburg-Eppendorf; University Hospital of Essen, Department of Bone Marrow Transplantation, Essen; Munich Oncology Practice, MVZ Elisenhof, Munich; Hematology & Oncology Practice, Plüderhausen; Hematology & Oncology Group Practice, Regensburg; Medical Treatment Centre Osthessen Ltd., Hematology & Oncology Practice, Fulda; Hematology & Oncology Practice, Erlangen; Hematology Practice, Wendlingen; Medical Treatment Centre am Bruderwald, Hematology & Oncology Practice, Bamberg; Hematology & Oncology Practice, Lörrach; Hematology & Oncology Practice, Villingen-Schwenningen; Hematology & Oncology Practice, Trier; Internist, Hematology & Oncology Practice, München; Hospital of Krefeld, Medical Clinic II, Krefeld; Hematology & Oncology Practice, Rosenheim, Germany; Hematology & Oncology Practice, Koblenz, Germany
منابع مشابه
ارزیابی میزان جهش JAK2V617F در بیماران میلو پرولیفراتیو مزمن به روش AS-RT-PCR
Background and Aim: The JAK2 is an acquired mutation that is observed in majority of patients with classical Philadelphia-negative Myeloproliferative neoplasms that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF). This acquired mutation is characterized by a G to T transversion at nucleotide 1849 in exon 12 of the JAK2 gene, leading to a substitution ...
متن کاملEvaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-PCR
Abstract Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V617F mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p, leading to a substitution of valine to phenylalanine at amino acid position 617 in the JAK2 protein. Methods In this study we evaluated RNA from 89 pati...
متن کاملGenetic predisposition for chemotherapy-induced neuropathy in multiple myeloma.
INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-1127, 2010 4. Pardanani A, Gotlib JR, Jamieson C, et al: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789796, 2011 5. Santos FP, Kantarjian HM, Jain N, et al: Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythem...
متن کاملImpact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
Most patients with polycythemia vera (PV) and half of essential thrombocythemia (ET) possess an activating JAK2V617F mutation. The objective of this study was to better define the effect of JAK2V617F mutant allele burden on clinical phenotypes in Chinese patients, especially thrombosis. By real-time polymerase chain reaction (RT-PCR), the JAK2V617F mutation burden was detected in 170 JAK2V617F-...
متن کاملImpact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
OBJECTIVE The JAK2V617F mutation is present in the majority of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The impact of this mutation on disease phenotype in ET and PMF is still a matter of discussion. This study aims to determine whether there are differences in clinical presentation and disease outcome between ET and PMF patients with and without the JAK2V61...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 94 1 شماره
صفحات -
تاریخ انتشار 2009